FDA wants Alexion to clean up

Share this article:

Alexion Pharmaceuticals has run afoul of the FDA. Again. The Wall Street Journal reports that FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices that need to be fixed through efforts such as “enhanced training around gowning procedures, more frequent environmental monitoring,” and other changes to literally clean things up.

The WSJ notes that Alexion asserted in a Securities and Exchange Commission filing that addressing the FDA's concerns won't hurt its financial status. The Journal also notes that this latest report is part of a larger string of citations, which have included a March 2013 warning letter and a bad review after a 2012 inspection.

Soliris costs around $450,000 a year and is indicated for patients with paroxysmal nocturnal hemoglobinuria. The condition destroys red blood cells.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.